The 2021 transcripts of 433 pharmaceutical companies are released!

A few days ago, the 2021 annual report disclosure of listed companies has come to an e.

Two 100 billion revenue leaders lead the way, Fosun and Heavy Pharmaceuticals have a growth rate of over 20%

Top 10 pharmaceutical companies by revenue in 2021 (unit: 100 million yuan)

From the perspective of revenue, there will be as many as 47 pharmaceutical companies with over 10 billion yuan in 2021, an increase of 2 compared with 202 Among the TOP10 companies, Shanghai Pharmaceuticals topped the list with a breakthrough of 200 billion yuan, and Jointown also reached a new hi.

Shanghai Pharmaceuticals: Revenue in 2021 will be 218 billion yuan, a year-on-year increase of 14

Jointown: Revenue in 2021 will be 124 billion yuan, a year-on-year increase of 14

58 net profit exceeded 1 billion! The first 10 billion pharmaceutical company was born, Mindray, Xinhechen.

In terms of net profit, 58 pharmaceutical companies have a net profit of more than 1 billion yu.

Zhifei Bio: Net profit of 12 billion yuan, a year-on-year increase of more than 20

Xinhecheng: Net profit reached a new high, breaking through the 4 billion yuan mark, a year-on-year increase of more than 2

18 gross profit margins exceed 90%! Science and Technology Innovation Board dominates the top 10 screens, and Bio-Tech ranks in the top five

TOP10 gross profit margin of pharmaceutical companies in 2021

From the perspective of gross profit margin, 18 pharmaceutical companies exceed 90%, and among the TOP10, except for Wuwu Biology and Yiqiao Shenzhou, 8 are from the Science and Technology Innovation Boa.

Wuwu Biology: In 2021, the revenue will be 808 million yuan, the net profit will be 338 million yuan, an increase of more than 20%, and a gross profit margin of 97

Bio-Tech: In 2021, the revenue will be 837 million yuan, a year-on-year increase of 3523%; the net profit will be 894 million yuan, a year-on-year increase of 1196%, and the gross profit margin will be 97

The annual report of 6 pharmaceutical companies is "difficult to give birth"

April 30 is the deadline for the disclosure of A-share statutory audit annual repor.

From the perspective of the reasons, it is not only affected by the epidemic situation, but also due to factors such as the inability to reach an agreement with the audit institution, and some companies have been punished by the regulatory authorities befo.

Industry analysts said that the failure of listed companies to disclose annual reports on time has violated the relevant provisions of the Securities Law, and may involve situations such as the implementation of delisting risk warnings or termination of listing required by the new delisting regulatio.

Performance of A-share pharmaceutical companies in 2021